Alcohol, drugs and medication in pregnancy [[electronic resource] ] : the long-term outcome for the child / / edited by Philip M. Preece, Edward P. Riley |
Pubbl/distr/stampa | London, : Mac Keith Press, 2011 |
Descrizione fisica | 1 online resource (697 p.) |
Disciplina | 618.32686 |
Altri autori (Persone) |
PreecePhilip M
RileyEdward P |
Collana | Clinics in developmental medicine |
Soggetto topico |
Alcoholism in pregnancy
Drug abuse in pregnancy Fetus - Effect of drugs on Fetus - Effect of tobacco on Pregnant women - Alcohol use Pregnant women - Drug use Pregnant women - Tobacco use |
Soggetto genere / forma | Electronic books. |
ISBN |
1-908316-29-2
1-907655-99-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; Authors' Appointments; 1. Introduction; Section 1 Neuroteratogenesis - Epidemiology And Pathology; 2. Epidemiology Of Drug And Alcohol Use During Pregnancy; 3. Normal And Abnormal Embryogenesis Of The Mammalian Brain; Section 2. Long-Term Effects Of Major Prescribed Medications; 4. Epilepsy In Pregnancy And The Effect Of Prenatal Antiepileptic Medication; 5. Neurodevelopment Of Children Exposed To Antidepressant And Antipsychotic Medications During Pregnancy; Section 3. Long-Term Effects Of Drugs Of Abuse
6. Diagnosis Of Fetal Alcohol Syndrome: Emphasis On Early Detection7. The Effects Of Prenatal Alcohol Exposure On Brain And Behaviour; 8. Effect Of Drugs Of Abuse On The Fetus: Cocaine And Opiates Including Heroin; 9. Cannabis Use During Pregnancy: Its Effects On Offspring From Birth To Young Adulthood; 10. In Utero Exposure To The Popular 'Recreational' Drugs Mdma (Ecstasy) And Methamphetamine (Ice, Crystal): Preliminary Findings; 11. The Short-Term And Long-Term Developmental Consequences Of Maternal Smoking During Pregnancy Section 4. Intervention Strategies To Reduce The Impact Of Drugs And Alcohol In Pregnancy12. Management Of The Effects Of Prenatal Drugs In Children Of Drug-Abusing Parents; 13. Prenatal And Postnatal Intervention Strategies For Alcohol-Abusing Mothers In Pregnancy; 14. Cognitive And Behavioural Interventions To Ameliorate The Effects Of Fetal Alcohol Spectrum Disorders In Children And Adolescents: Promoting Positive Outcomes; 15. Fetal Teratogen Syndromes: Psychiatric Aspects And Management 16. Recommended Management Of Common Medical Problems In Pregnancy: Advice From Specialist AgenciesIndex |
Record Nr. | UNINA-9910456279903321 |
London, : Mac Keith Press, 2011 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Alcohol, drugs and medication in pregnancy [[electronic resource] ] : the long-term outcome for the child / / edited by Philip M. Preece, Edward P. Riley |
Pubbl/distr/stampa | London, : Mac Keith Press, 2011 |
Descrizione fisica | 1 online resource (697 p.) |
Disciplina | 618.32686 |
Altri autori (Persone) |
PreecePhilip M
RileyEdward P |
Collana | Clinics in developmental medicine |
Soggetto topico |
Alcoholism in pregnancy
Drug abuse in pregnancy Fetus - Effect of drugs on Fetus - Effect of tobacco on Pregnant women - Alcohol use Pregnant women - Drug use Pregnant women - Tobacco use |
ISBN |
1-908316-29-2
1-907655-99-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; Authors' Appointments; 1. Introduction; Section 1 Neuroteratogenesis - Epidemiology And Pathology; 2. Epidemiology Of Drug And Alcohol Use During Pregnancy; 3. Normal And Abnormal Embryogenesis Of The Mammalian Brain; Section 2. Long-Term Effects Of Major Prescribed Medications; 4. Epilepsy In Pregnancy And The Effect Of Prenatal Antiepileptic Medication; 5. Neurodevelopment Of Children Exposed To Antidepressant And Antipsychotic Medications During Pregnancy; Section 3. Long-Term Effects Of Drugs Of Abuse
6. Diagnosis Of Fetal Alcohol Syndrome: Emphasis On Early Detection7. The Effects Of Prenatal Alcohol Exposure On Brain And Behaviour; 8. Effect Of Drugs Of Abuse On The Fetus: Cocaine And Opiates Including Heroin; 9. Cannabis Use During Pregnancy: Its Effects On Offspring From Birth To Young Adulthood; 10. In Utero Exposure To The Popular 'Recreational' Drugs Mdma (Ecstasy) And Methamphetamine (Ice, Crystal): Preliminary Findings; 11. The Short-Term And Long-Term Developmental Consequences Of Maternal Smoking During Pregnancy Section 4. Intervention Strategies To Reduce The Impact Of Drugs And Alcohol In Pregnancy12. Management Of The Effects Of Prenatal Drugs In Children Of Drug-Abusing Parents; 13. Prenatal And Postnatal Intervention Strategies For Alcohol-Abusing Mothers In Pregnancy; 14. Cognitive And Behavioural Interventions To Ameliorate The Effects Of Fetal Alcohol Spectrum Disorders In Children And Adolescents: Promoting Positive Outcomes; 15. Fetal Teratogen Syndromes: Psychiatric Aspects And Management 16. Recommended Management Of Common Medical Problems In Pregnancy: Advice From Specialist AgenciesIndex |
Record Nr. | UNINA-9910781264103321 |
London, : Mac Keith Press, 2011 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Alcohol, drugs and medication in pregnancy : the long-term outcome for the child / / edited by Philip M. Preece, Edward P. Riley |
Edizione | [1st ed.] |
Pubbl/distr/stampa | London, : Mac Keith Press, 2011 |
Descrizione fisica | 1 online resource (697 p.) |
Disciplina | 618.32686 |
Altri autori (Persone) |
PreecePhilip M
RileyEdward P |
Collana | Clinics in developmental medicine |
Soggetto topico |
Alcoholism in pregnancy
Drug abuse in pregnancy Fetus - Effect of drugs on Fetus - Effect of tobacco on Pregnant women - Alcohol use Pregnant women - Drug use Pregnant women - Tobacco use |
ISBN |
1-908316-29-2
1-907655-99-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title; Copyright; Contents; Authors' Appointments; 1. Introduction; Section 1 Neuroteratogenesis - Epidemiology And Pathology; 2. Epidemiology Of Drug And Alcohol Use During Pregnancy; 3. Normal And Abnormal Embryogenesis Of The Mammalian Brain; Section 2. Long-Term Effects Of Major Prescribed Medications; 4. Epilepsy In Pregnancy And The Effect Of Prenatal Antiepileptic Medication; 5. Neurodevelopment Of Children Exposed To Antidepressant And Antipsychotic Medications During Pregnancy; Section 3. Long-Term Effects Of Drugs Of Abuse
6. Diagnosis Of Fetal Alcohol Syndrome: Emphasis On Early Detection7. The Effects Of Prenatal Alcohol Exposure On Brain And Behaviour; 8. Effect Of Drugs Of Abuse On The Fetus: Cocaine And Opiates Including Heroin; 9. Cannabis Use During Pregnancy: Its Effects On Offspring From Birth To Young Adulthood; 10. In Utero Exposure To The Popular 'Recreational' Drugs Mdma (Ecstasy) And Methamphetamine (Ice, Crystal): Preliminary Findings; 11. The Short-Term And Long-Term Developmental Consequences Of Maternal Smoking During Pregnancy Section 4. Intervention Strategies To Reduce The Impact Of Drugs And Alcohol In Pregnancy12. Management Of The Effects Of Prenatal Drugs In Children Of Drug-Abusing Parents; 13. Prenatal And Postnatal Intervention Strategies For Alcohol-Abusing Mothers In Pregnancy; 14. Cognitive And Behavioural Interventions To Ameliorate The Effects Of Fetal Alcohol Spectrum Disorders In Children And Adolescents: Promoting Positive Outcomes; 15. Fetal Teratogen Syndromes: Psychiatric Aspects And Management 16. Recommended Management Of Common Medical Problems In Pregnancy: Advice From Specialist AgenciesIndex |
Record Nr. | UNINA-9910811033603321 |
London, : Mac Keith Press, 2011 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy [[electronic resource] /] / Bengt Källén |
Autore | Källén Bengt |
Pubbl/distr/stampa | New York, : Nova Biomedical Books, c2009 |
Descrizione fisica | 1 online resource (464 p.) |
Disciplina | 618.3/2 |
Collana | Pregnancy and infants : medical, psychological and social issues series |
Soggetto topico |
Fetus - Effect of drugs on
Pregnant women - Drug use |
Soggetto genere / forma | Electronic books. |
ISBN | 1-61728-374-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910460022203321 |
Källén Bengt | ||
New York, : Nova Biomedical Books, c2009 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy [[electronic resource] /] / Bengt Källén |
Autore | Källén Bengt |
Pubbl/distr/stampa | New York, : Nova Biomedical Books, c2009 |
Descrizione fisica | 1 online resource (464 p.) |
Disciplina | 618.3/2 |
Collana | Pregnancy and infants : medical, psychological and social issues series |
Soggetto topico |
Fetus - Effect of drugs on
Pregnant women - Drug use |
ISBN | 1-61728-374-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910785180203321 |
Källén Bengt | ||
New York, : Nova Biomedical Books, c2009 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy [[electronic resource] /] / Bengt Källén |
Autore | Källén Bengt |
Edizione | [1st ed.] |
Pubbl/distr/stampa | New York, : Nova Biomedical Books, c2009 |
Descrizione fisica | 1 online resource (464 p.) |
Disciplina | 618.3/2 |
Collana | Pregnancy and infants : medical, psychological and social issues series |
Soggetto topico |
Fetus - Effect of drugs on
Pregnant women - Drug use |
ISBN | 1-61728-374-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Abbreviations Used -- Chapter 1 -- A Short history of the study of maternal drug Use and delivery outcome -- The alert clinician -- Epidemiological studies -- References -- Chapter 2 -- The practical consequences of drug effects on delivery outcome -- 1. Introduction of a New drug into a market -- 2. A woman has Used the drug in early pregnancy -- 3. To prescribe a drug to a pregnant woman -- 4. A malformed infant was born and the mother remembers Having Taken a specific drug. -- A causal effect? -- Chapter 3 -- The Swedish health registers used and variables studied -- The following records are included: -- MHV1 -- MHV2 -- FV1 -- FV2 -- The following data were used -- Year of delivery -- Maternal age -- Parity -- Smoking in early pregnancy -- Number of previous miscarriages -- Body Mass Index (BMI) -- Country of birth -- Family situation -- Work outside home -- Maternal education -- Maternal drug use -- Multiple births -- Maternal delivery diagnoses -- Delivery mode -- Pregnancy duration in completed weeks -- Infant sex -- Birth weight in gram -- Intrauterine growth -- Infant neonatal diagnoses -- Low Apgar score -- Congenital malformations in infants -- Any congenital malformation -- Chapter 4 -- Advantages and disadvantages of the study material -- Advantages -- Disadvantages -- Exposure information -- Outcome information -- Information on confounding factors -- References -- Chapter 5 -- Strategy of analysis -- Statistical notes -- References -- Chapter 6 -- Data on women and infants recorded in the Medical Birth Register during -- 1996-2005 -- Data on pregnancy outcome in all deliveries in the Medical Birth Register during 1996-2005 -- 1. Preterm birth, low birth weight, large birth weight, intrauterine growth -- 2. Infant sex and multiple births.
3. Maternal and infant diagnoses and infant outcome -- 4. Congenital malformations -- Chapter 7 -- Antacids -- Characteristics of women Using antacids -- Outcome after maternal Use of antacids -- Infant sex -- Multiple births -- Summary -- References -- Chapter 8 -- Drugs Used for gastric ulcer and gastro-oesophageal reflux -- Characteristics of women Using drugs for gastric ulcer or gastro-oesophageal reflux -- Outcome after maternal Use of drugs for stomach ulcer or gastro-oesophageal reflux -- Infant sex -- Multiple births -- Sucralfate -- Effects of concomitant drug use -- Summary -- References -- Chapter 9 -- Drugs Used for functional intestinal symptoms -- Characteristics of women Using drugs for functional intestinal symptoms -- Outcome after maternal Use of drugs for functional intestinal symptoms -- Infant sex -- Multiple births -- Summary -- References -- Chapter 10 -- Anti-Emetic drugs -- Outcome after maternal Use of antiemetic drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 11 -- Bile acid preparations -- Outcome after maternal Use of Bile Acid preparations -- Infant sex -- Multiple birth -- Infant mortality -- Summary -- Chapter 12 -- Laxatives -- Characteristics of women Using laxatives -- Outcome after maternal Use of laxatives -- Infant sex -- Multiple births -- Summary -- References -- Chapter 13 -- Drugs Used as antidiarrhoics, intestinal anti-Infectives, or at inflammatory bowel disease -- Characteristics for women Using drugs as antidiarrhoics, intestinal anti-infectives, or at inflammatory bowel disease -- Outcome after maternal use of drugs Used as antidiarrhoics, intestinal anti-infectives, or at inflammatory bowel disease -- Infant sex -- Multiple births -- Summary -- References -- Chapter 14 -- Anti-Obesity drugs -- Characteristics of women Using anti-Obesity drugs. Outcome after maternal Use of anti-Obesity drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 15 -- Digestives, including enzymes -- Characteristics of women Using digestive drugs -- Outcome after maternal Use of digestive drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 16 -- Drugs for diabetes -- Characteristics of women Using antidiabetic drugs -- Outcome after maternal Use of antidiabetic drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 17 -- Vitamins and minerals -- Characteristics of women Using vitamins or minerals -- Outcome after maternal Use of vitamins and minerals -- Infant sex -- Multiple births -- Summary -- References -- Chapter 18 -- Anabolic steroids -- Summary -- References -- Chapter 19 -- Anticoagulants -- Characteristics of women Using anticoagulant drugs -- Outcome after maternal Use of anticoagulants -- Infant sex -- Multiple births -- Summary -- References -- Chapter 20 -- Haemostatics -- Characteristics of women Using Haemostatics -- Outcome after maternal Use of haemostatics -- Infant sex -- Multiple births -- Infant mortality -- K-vitamin -- Summary -- References -- Chapter 21 -- Vitamin B12 and folic acid -- Characteristics of women Using vitamin B12 or folic acid -- Outcome after maternal Use of vitamin B12 or folic acid -- Infant sex -- Multiple births -- Summary -- References -- Chapter 22 -- Drugs for cardiac diseases -- Characteristics of women Using drugs for cardiac diseases -- Outcome after maternal Use of cardiac drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 23 -- Antihypertensives -- Characteristics of women Using drugs for antihypertensives -- Outcome after maternal Use of antihypertensives -- Infant sex -- Multiple births -- Summary. References -- Chapter 24 -- Diuretics -- Characteristics of women Using diuretics -- Outcome after maternal Use of diuretics -- Infant sex -- Multiple births -- Summary -- References -- Chapter 25 -- Serum lipid reducing agents -- Characteristics of women Using lipid reducing drugs -- Outcome after maternal Use of lipid reducing drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 26 -- Dermatological drugs -- Characteristics of women Using dermatological drugs -- Outcome after maternal Use of dermatological drugs -- Infant sex -- Multiple births -- Topical corticosteroids -- Other dermatological drugs -- Summary -- References -- Chapter 27 -- Gynaecological drugs -- Characteristics of women Using anti-infectives or antiseptics vaginally -- Outcome after maternal Use of anti-infectives or antiseptics vaginally -- Infant sex -- Multiple births -- Summary -- References -- Chapter 28 -- Prolactine inhibitors and dopamine agonists -- Characteristics of women Using prolactine inhibitors or dopamine agonists -- Outcome after maternal Use of prolactine inhibitors or dopamine agonists -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 29 -- Oral contraceptives -- Characteristics of women Using oral contraceptives in early pregnancy -- Outcome after maternal Use of oral contraceptives in early pregnancy -- Infant sex -- Multiple births -- Summary -- References -- Chapter 30 -- Sex hormones Other than oral contraceptives -- Characteristics of women Using progestogen drugs -- Outcome after maternal Use of progestogens -- Infant sex -- Multiple births -- Summary -- References -- Chapter 31 -- Ovulation stimulants -- Characteristics of women Using ovarian stimulants -- Outcome after maternal Use of ovarian stimulants -- Infant sex -- Multiple births -- Summary -- References. Chapter 32 -- Urologicals -- Characteristics of women using urological drugs -- Outcome after maternal Use of urologics -- Infant sex -- Multiple births -- Summary -- Chapter 33 -- Hypophyseal and hypothalamic hormones (except gonadotrophines) and analogues -- Characteristics of women Using hypophyseal or hypothalamic drugs -- Outcome after maternal Use of hypophyseal hormones other than gonadotrophines -- Infant sex -- Multiple births -- Summary -- References -- Chapter 34 -- Corticosteroids Used systemically -- Characteristics of women Using glucocorticoids -- Outcome after maternal Use of glucocorticosteroids -- Infant sex -- Multiple births -- Summary -- References -- Chapter 35 -- Thyroid drugs -- Characteristics of women Using thyroid drugs -- Thyroid hormones -- Thyreostatics -- Outcome after maternal Use of thyroid drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 36 -- Antibiotics Used systemically -- Characteristics of women Using antibiotics -- Outcome after maternal Use of antibiotics -- Infant sex -- Multiple births -- Trimethoprim -- Quinolone derivatives -- Summary -- References -- Chapter 37 -- Antimycotics Used systemically -- Characteristics of women Using systemic antimycotics -- Outcome after maternal Use of systemic antimycotics -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 38 -- Tuberculostatic drugs -- Characteristics of women Using tuberculostatic drugs -- Outcome after maternal Use of tuberculostatic drugs -- Infant sex -- Multiple births -- Infant mortality -- Pregnancy duration and infant birth weight at maternal use of tuberculostatic drugs -- Summary -- References -- Chapter 39 -- Anti-Virus drugs -- Characteristics of women Using antivirus drugs -- Outcome after maternal Use of antivirus drugs -- Infant sex -- Multiple births -- Summary -- References. Chapter 40. |
Record Nr. | UNINA-9910810938703321 |
Källén Bengt | ||
New York, : Nova Biomedical Books, c2009 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
Descrizione fisica | 1 online resource (907 p.) |
Disciplina | 618.32 |
Altri autori (Persone) | SchaeferChristof |
Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
Soggetto genere / forma | Electronic books. |
ISBN |
1-281-01913-5
9786611019136 0-08-054977-2 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
Record Nr. | UNINA-9910458841103321 |
Amsterdam ; ; New York, : Elsevier, 2007 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
Descrizione fisica | 1 online resource (907 p.) |
Disciplina | 618.32 |
Altri autori (Persone) | SchaeferChristof |
Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
ISBN | 9780080549774 (Electronic Book) |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
Record Nr. | UNINA-9910784615103321 |
Amsterdam ; ; New York, : Elsevier, 2007 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Drugs during pregnancy and lactation : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
Descrizione fisica | 1 online resource (907 p.) |
Disciplina | 618.32 |
Altri autori (Persone) | SchaeferChristof |
Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
ISBN | 9780080549774 (Electronic Book) |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
Record Nr. | UNINA-9910828812503321 |
Amsterdam ; ; New York, : Elsevier, 2007 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Health aspects of pregnancy and childbirth: United States, 1982 / / by Elsie R. Pamuk and William D. Mosher |
Autore | Pamuk Elsie |
Pubbl/distr/stampa | Hyattsville, Md. : , : U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Health Statistics, , 1988 |
Descrizione fisica | 1 online resource (iv, 74 pages) : illustrations |
Collana |
Vital & health statistics. Series 23, Data from the national survey of family growth
DHHS publication |
Soggetto topico |
Prenatal care - United States
Pregnant women - Drug use - United States Pregnant women - Tobacco use - United States Pregnant women - Alcohol use - United States Birth weight, Low - United States Childbirth - Economic aspects - United States Health surveys - United States Birth weight, Low Childbirth - Economic aspects Health surveys Pregnant women - Drug use Prenatal care |
Soggetto genere / forma |
Statistics.
Statistics |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Altri titoli varianti | Health aspects of pregnancy and childbirth |
Record Nr. | UNINA-9910711646803321 |
Pamuk Elsie | ||
Hyattsville, Md. : , : U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Health Statistics, , 1988 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|